We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Actinium Pharmaceuticals Announces Filing of Provisional Patent Application
News

Actinium Pharmaceuticals Announces Filing of Provisional Patent Application

Actinium Pharmaceuticals Announces Filing of Provisional Patent Application
News

Actinium Pharmaceuticals Announces Filing of Provisional Patent Application

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Actinium Pharmaceuticals Announces Filing of Provisional Patent Application"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Actinium Pharmaceuticals, Inc. has announced that it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) pertaining to Iomab-B, the Company's Iodine-131 labeled anti-CD45 antibody. This provisional patent application represents the second provisional patent application filing related to Iomab-B following the Company's June 24, 2015 filing for infusion administration of Iomab-B.

A provisional patent application is a legal document that establishes an early priority date for the benefit of claiming "first to file" status against other companies or individuals that may want to file a subsequent patent with similar claims. Kaushik J. Dave, Ph.D., MBA, Chief Executive Officer of Actinium Pharmaceuticals said, "This provisional patent application represents another valuable addition to our intellectual property portfolio. We remain committed to the strategic enhancement of our intellectual property portfolio in alignment with our development of targeted payload immunotherapeutics."

Sandesh Seth, Executive Chairman of Actinium Pharmaceuticals said, "2016 will be a transformational year for Actinium as we transition to a later stage company with the commencement of the Iomab-B Phase 3 pivotal trial and the Actimab-A Phase 2 clinical trial. The strengthening of our intellectual property portfolio is an integral aspect of Actinium's growth and today's provisional patent application demonstrates our commitment to this goal."

Actinium's broad intellectual property portfolio includes 39 issued and pending patents in the U.S. and internationally. This includes 7 issued patents in the United States, 2 pending patents in the United States and 30 issued or pending international patents. The Company's patent portfolio encompasses the use of alpha emitting isotopes attached to monoclonal antibodies, methods for manufacturing key components of its product candidates and methods for manufacturing finished product candidates for use in cancer treatment.

Advertisement